



Grzegorz Łukasik<sup>1\*</sup> , Mateusz Guziak<sup>2\*</sup> , Zuzanna Bastrzyk<sup>1</sup> , Olga Szot<sup>3</sup> , Bartosz Kamil Sobocki<sup>4</sup> 

<sup>1</sup>Scientific Circle of Oncology and Radiotherapy, Medical University of Gdansk, Gdańsk, Poland

<sup>2</sup>Department of Family Medicine, Faculty of Medicine, Medical University of Gdansk, Gdańsk, Poland

<sup>3</sup>Independent Public Health Care Institution of the Ministry of the Interior and Administration in Gdańsk, Poland

<sup>4</sup>Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdańsk, Poland

\*These authors contributed equally to this work, and should be considered as co-first authors

# The use of cannabinoids and alternative therapies in chronic pain management: a narrative review

## Abstract

Palliative care patients experience pain daily which significantly lowers their quality of life. Chronic pain is one of the main reasons why people contact health professionals, and its prevalence is about 20% in Europe and the United States. Comprehensive and sufficient pain management is often limited to medical facilities whereas patients suffering from chronic pain staying in their households often receive incomplete analgesia. Pharmacological recommendations were described with specific indications and contraindications for therapeutic regimens in relation to cancer patients under palliative care. The addition of alternative pain management techniques to the pharmacological treatment can contribute to better pain control and even lower doses of opioids administered. On the other hand, state-of-the-art studies evaluating their efficiency and mechanism of action are missing. This study summarizes a variety of alternative pain management methods and mechanisms behind their analgesic and co-analgesic effects that contribute to maximizing the pharmacological effect of analgesic drugs. This study aimed to gather alternative pain control options and assess their efficiency, status, and potential in palliative care settings. Moreover, this review tries to evaluate whether they are scientifically evidence-based or not.

*Palliat Med Pract 2024; 18, 3: 150–162*

**Keywords:** adjuvants, analgesics, pain, supportive care, palliative care, symptom management

## Introduction

Pain is considered a major problem in the world affecting individual patients as well as the economy and medicine [1]. The chronic pain prevalence is estimated

to be nearly 20% in the United States and Europe, while its management cost in 2010 was between 560 and 635 billion dollars solely in the US [2–5]. Chronic pain is one of the main reasons why people contact health professionals [2]. It indicates its high impact on both

### Address for correspondence:

Mateusz Guziak

Department of Family Medicine, Faculty of Medicine, Medical University of Gdansk, Dębinki 2, 80–211 Gdańsk, Poland

e-mail: mateusz.guziak@gumed.edu.pl



Palliative Medicine in Practice 2024; 18, 3: 150–162

Copyright © 2024 Via Medica, ISSN 2545–0425, e-ISSN 2545–1359

DOI: 10.5603/pmp.98210

Received: 13.11.2023 Accepted: 18.01.2024 Early publication date: 19.01.2024

This article is available in open access under Creative Commons Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.

the physical and mental state and the patient's overall quality of life. On the other hand, both physical and mental state influence pain perception by mitigating or enhancing its sensation. It demonstrates how complex pain issue is [6]. Effective treatment of pain and concurrent symptoms in patients receiving end-of-life care and palliative care is essential. It improves the patient's life quality significantly. The problem of pain in this group is very prevalent, in advanced, metastatic, and terminal cancer 54.6% of patients experience pain in more than one location, exacerbating patients' distress and suffering [7, 8]. It often coexists with fatigue, insomnia, anxiety, anorexia, depression, nausea and vomiting [8, 9]. Inadequate treatment of the pain affects more than 30% of cancer patients and results from many reasons, related to both patients and providers [8]. The main problem seems to be the lack of knowledge of the available methods of pain treatment, analgesics, and coping with the side effects of the treatment [7, 8]. To improve the management of pain it is important to provide palliative care as soon as possible to those with life-limiting illnesses [10]. Older patients accept pain as an integral part of their illness more often and cope better than younger patients, so they are at a higher risk of inadequate pain management [11].

According to the reports made in Canada in 2017 and 2021 about 70% of seriously ill home care patients from Ontario suffer from severe pain [10]. The DEMETRA study including 865 patients with advanced cancer has demonstrated how specialist palliative care helps reduce pain in patients treated at home, in hospital and hospice [12]. The COVID-19 pandemic has also affected pain management. A study of 103 cancer patients determined that the patients with cancer had moderate to severe pain intensity with low levels of self-management and self-efficacy towards that pain during the pandemic. Thirty-two per cent (32.1%) of the patients needed additional help or support; 18.25% thought an epidemic affected pain management; 7.41% reported an increase in pain intensity [13]. The group was too small to make a general conclusion, but it shows that patients were concerned about pain management during the pandemic. The pharmacological methods of pain management are crucial, however, they should not be used alone, as a simultaneous application of non-pharmacological techniques might improve the effect. Pharmacological treatment can be followed by supportive care such as rehabilitation, relaxation techniques and lifestyle modifications [9, 14]. The following review presents methods that are not commonly used and still are a matter of scientific discussion. The main aim of this review is, to sum up data about cannabinoids and

alternative methods of pain management with a focus on the palliative care setting, indicate their efficiency, positives, and negatives, and draw conclusions about what should be done to make the patient's quality of life better.

## Methods

This narrative review focuses on the problem of pain management in chronic conditions, analysing human clinical studies. The search was performed using MEDLINE and Google Scholar. Analysing specific methods, the following search queries were used: "cannabinoids and pain", "music therapy and pain", "cognitive behavioural therapy and pain", "physical exercise and pain", "biofeedback and pain" and "acupuncture and pain". All articles were assessed by title, and abstract and then qualified for full-text analysis. For every paragraph, full-text articles were reviewed at least by two co-authors. The studies focusing solely on acute pain, case reports, as well as studies published only as abstracts, posters or reports from conferences and studies written in a language other than English were excluded from the analysis. The studies published before the 2000 year were excluded from the analysis, except for one study (1999) that was used to depict historical context.

## Medical cannabis and cannabinoids

A constantly growing number of analgesics abuse, including the worldwide opioid crisis creates the need for new treatment modalities and active substances, incorporating medical cannabis and cannabinoids used for pain [15–17]. The two main active substances in cannabis are delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), both causing analgesia, but, most importantly, CBD does not have a psychoactive effect [18]. There are also endogenous cannabinoids, anandamide (arachidonoyl ethanolamide) and 2-Ara-Gl (2-arachidonoglycerol). They regulate signal transduction pathways by binding cannabinoid receptors CB<sub>1</sub> (expressed mainly in the central nervous system and sensory neurons of dorsal root ganglia) and CB<sub>2</sub> (mainly in the cells of the immune system, microglia, astrocytes, and peripheral nerves), causing activation of G<sub>i</sub> protein which inhibits adenyl cyclase. The precise localization and effects of receptor CB<sub>3</sub> are still the subject of intensive studies. Endogenous cannabinoids can be produced in several body tissues and affect synergistically via different mechanisms, preventing the degradation of the active form or initiating binding to a specific receptor. It's called the "entourage effect" [19]. Chronic pain increases

the amount of CB<sub>2</sub> receptors on peripheral cells, which changes the pain signals pathway and is one of the impacts of cannabinoids on pain processing [20]. Anandamide can reduce cisplatin-induced CIPN (chemotherapy-induced neuropathic pain) by affecting CB<sub>1</sub>. Increasing the level of anandamide by using an inhibitor of specific hydrolysis prevents hyperalgesia [21, 22]. The neuropathic component can be up to 40% of pain in cancer patients, so cannabinoids can potentially be effective in therapy [21].

Using cannabinoids has yet to be standardized globally, primarily due to the contradicting findings of various studies. The legalization of medical cannabis and cannabinoids for treating chronic pain (mainly non-cancer related) in some countries (U.S., Australia) has resulted in many studies investigating its use. There is only moderate evidence of cannabinoids' effectiveness in chronic pain control and cannabinoids are not strongly recommended in therapy of cancer patients, due to potential reduction of quality of life and change of survival caused by ineffective therapy [23]. Moreover, it can be very difficult to obtain long-term conclusions.

A systemic review and meta-analysis of randomized clinical trials with moderate to high certainty evidence show that using non-inhaled medical cannabis or cannabinoids by patients living with chronic pain, compared with placebo, may cause a small and very small increase of pain relief, but in fact, does not improve functioning [24]. Adding cannabinoids may be recommended by some experts to reduce opioid doses in patients with severe side effects and ineffective pain control, but placebo-controlled, randomized clinical trials are needed [25]. The placebo-controlled randomized study of 25 patients receiving methadone therapy for opioid use disorder showed that adding delta-9-tetrahydrocannabinol (THC) (especially in a dose of 20 mg) modulated pain sensitivity in this cohort. However, it changed self-reported rather than experimental pain sensitivity measures [26, 27]. Medical cannabis legalization in some states in the U.S. has indeed reduced opioid use and mortality from opioid overdose [28]. However, there are also some negative reports about the synergistic effect of opioids with THC. Within-subject, double-blind, randomized, placebo-controlled study of 37 subjects with knee osteoarthritis-related pain revealed no significantly improved analgesic effect for clinical pain severity and physical functioning with the use of the hydro-morphone-dronabinol combination [29]. Another meta-analysis of pre-clinical and clinical studies by Nielsen et al. [30] proved no effect of cannabinoids on opioid-sparing. Noori et al. [31] meta-analysis showed low certainty in this matter.

Recently, many systematic reviews and meta-analyses were published. McParland et al. [32] demonstrated that THC might reduce peripheral or central neuropathic pain with moderate grade certainty of evidence based on the group of 1051 patients in comparison to placebo. Conversely, the newest studies have the opposite results. Oral capsules of THC alone and in combination with cannabidiol had no effect on peripheral neuropathic pain in the group of 145 patients with at least one prior line of evidence-based treatment [33]. Although the systematic review with meta-analysis and trial sequential analysis conducted by Barakji based on 7017 participants confirmed the positive impact on chronic pain, both effect sizes were below predefined minimal important differences. These results are supported in Wang's et al. [22] meta-analysis. Moreover, the analysis indicated no influence on cancer and acute pain with an increased risk of non-serious adverse events [34]. Zeraatkar's meta-analysis defined this risk as limited but emphasised the risk of rare serious adverse events [35]. Another meta-analysis by Bilbao et al. [36] proved that dronabinol and nabiximols reduced chronic pain with moderate evidence. This inconsistency raises the issue of risk related to generalized conclusions in this group of drugs. Every applied active substance should be investigated in a specific setting and clinical application.

There were also some clinical trials in specific diseases. Cannabidiol chewing gum was ineffective in the treatment of perceived pain in irritable bowel syndrome [37]. However, a meta-analysis by Doeve et al. [38] revealed an alleviating effect on patient-reported symptoms and increased quality of life scores after cannabinoids and phase 2b randomized placebo-controlled trial (CAPTIVATE) showed the significant impact of olorinab (an agonist of cannabinoid receptor 2) on abdominal pain (moderate to severe) reduction [39]. Similarly, inhaled cannabis did not affect pain in the randomized clinical trial of patients with sickle cell disease [40]. The THC-CBD spray improved pain and spasticity in secondary progressive multiple sclerosis patients, but the conclusions of this study are limited by the low (n = 15) number of subjects [41]. However, another study (n = 20) confirmed it [42]. The effect on pain in fibromyalgia was also limited [43] and the lack of impact on abdominal pain was observed in a phase 2 study [44]. On the other hand, a multicentre, open-label, follow-on study (n = 380) proved the therapeutic effect of THC/CBD oromucosal spray in the management of neuropathic pain related to diabetes or allodynia [45] and this observation was further confirmed by double-blind, randomized, placebo-controlled parallel group study (n = 303) [46].

A study by Wallace [47] indicated that patients with low and high THC levels in the blood did not experience a decrease in pain intensity in diabetic neuropathy, whereas those whose THC levels were in the therapeutic range, experienced a positive effect, indicating the importance of appropriate dose. A study by Almog [48] also confirmed the determining effect of dose on the efficiency in chronic pain management.

Medical cannabis and cannabinoids may be considered as a part of pain management, especially in cases where a neuropathic component of ailments is highly probable. Adding cannabinoids can also potentially reduce doses of opioids. A combination of THC/CBD seems to be more effective than THC extract, possibly because of the “entourage effect”. However, some negative meta-analyses limit its applicability and show the lack of efficiency of this group, suggesting the use of cannabinoids only in some cases of non-cancer chronic pain [49]. Interestingly, Gedin et al. [50] indicated that a placebo might affect the outcome of many cannabinoid clinical trials, contributing significantly to pain reduction. Another problem might be the appropriate dose [51]. Therefore, there is a need for careful design of future studies, considering these effects.

## Non-pharmacological methods of alternative pain management

There are numerous methods of pain management that are non-pharmacological. Some of them were tested in clinical trials and they are summarized below.

### Music therapy

One of the potential methods of alleviating pain and supporting basic therapy is music therapy. The mechanism behind music therapy effectiveness may be explained by the descending pain modulatory system (DPMS) [52, 53], which can alter pain perception. By evoking an emotional response, music stimulates the central nervous system to down-regulate stress, anxiety and pain via the endocrine, autonomous and immune systems [54, 55]. Rhythm creates brain waves modulating the autonomous nervous system to lower heart rate, respiratory rate and both, systolic and diastolic pressure [54], to relax muscles [56], which the patient interprets as anxiety relief and fatigue reduction [57]. By shifting the balance from sympathetic to parasympathetic nervous system music therapy succeeds in increasing high-frequency variation in heart rate and improving peripheral circulation [57].

There are two methods to introduce music into the treatment process — music medicine and music therapy [58]. Music medicine involves passive listening

to pre-recorded music. Music therapy requires more active participation — while listening to live music, the patient works with a trained music therapist, such as performing breathing exercises, visualization or playing an instrument themselves. A meta-analysis summarized the outcomes of different studies comparing both methods and concluded that music therapy tends to be more engaging and better at changing a patient’s pain perception, and music medicine allows the administration of lower dosages of analgesics and normalizes vital parameters such as heart rate, respiration rate and blood pressure [58]. Despite the varying strengths of each method, there was no statistically significant difference in effectiveness between music medicine and music therapy in pain reduction [55, 58].

A randomized controlled trial conducted by Gutschell et al. [59] investigated the efficiency of music therapy plus standard therapy vs standard therapy alone in the reduction of pain in a group of 200 palliative care patients. Interestingly, a significant decrease in numeric rating scale pain was observed in the patients who underwent a single music therapy intervention based on therapist-guided autogenic relaxation and live music [59]. In a meta-analysis Li et al. [60] tried to establish the exact duration of music therapy for it to be the most effective in managing pain — it should last from 1 to 2 months.

Another multicenter randomized controlled trial of 104 palliative care patients called “Song of Life” was based on a three-session music therapy intervention working with a biographically meaningful song [61]. Although psychological quality of life was not improved, participants reported higher spiritual well-being and lower distress than in the control group [61]. Moreover, the reduction of cortisol and lower mean heart rate were confirmed [61]. Future studies should further evaluate the efficiency and cost-effectiveness of music therapy to assess the potential of the introduction of this treatment into clinical practice. Especially, when music therapy complementary to pharmacological treatment, has been described to enable opioid and non-opioid analgesic dosage reduction [52]. The possibility of minimizing the requirement of analgesics should be treated with reserve as not every study found this statistically significant [52]. Familiarity with music is also a valid aspect of music therapy — as it gives the patient comfort and a feeling of “control” over their treatment, further amplifying the analgesic effect [52, 59]. However, not every study which observed and admitted its relevance, found it statistically significant [52].

The addition of music therapy to pharmacological methods of pain management is promising, enabling it to reduce pain, alleviate anxiety and improve sleep

quality and overall quality of life [55, 60]. The main issue is heterogeneity between studies reporting on its use — each study has its own music therapy regimen. They differ in almost every aspect of therapy, e.g.: type of music, frequency and duration of each intervention, time of the follow-up, scales used to assess the pain intensity, and chosen control group. It is also prone to bias as most of the patients are already on analgesics when starting music therapy, making it almost impossible to distinguish the role of each treatment in pain management. The research on music therapy needs standardization in order to objectively state the extent of its use.

### Cognitive behavioural therapy

Another interesting psychological method of pain management is cognitive behavioural therapy (CBT) [61]. The mechanism behind CBT is explained by several theories one of them being the Gate Control Theory of Pain [62]. The aforementioned theory states that by stimulating various areas of the brain responsible for cognition, emotion and endocrine regulation, it is possible to down-regulate pain gating in the dorsal horns of the spinal cord [62]. Neuromatrix Theory developed from the Gate Control Theory of Pain and went further and stated that stressful external stimuli can distort the structure of tissues, including neural circuits [63]. Seminowicz et al. [64] tested whether CBT can alter the structure of the brain using MRI imaging which revealed changes in the prefrontal cortex, potentially leading to different pain perceptions [62].

Saxena et al. [65] in a pilot study compared the efficiency of CBT in combination with pregabalin vs. pregabalin alone in the management of neuropathic pain in post-therapeutic neuralgia. In an equally divided group of 40 patients, a significant decrease in pain intensity, depressive symptoms, and pain-related catastrophizing and the improvement in the quality of life were noted in the group receiving both, pharmacological and psychological treatment. NRS pain score was not significantly different in the two groups. However, significant downregulation of IL-6 was observed [66], which is one of the factors considered to be correlated with the prognosis and occurrence of pain [67, 68].

Another study by Rodin et al. [68] tested a modification of CBT called Emotion and symptom-focus management (EASA) intervention based on 8 weeks of psychotherapy in a group of palliative care patients with acute leukaemia. The investigators compared EASA in combination with standard care vs. standard care alone. The study showed a reduction of pain intensity and interference at 12 weeks as well as an alleviation of traumatic stress symptoms [68]. The

pain improvement after CBT treatment was also confirmed in studies regarding chronic low back pain and haemophilia [68, 69]. Although better management of pain after CBT was confirmed in fibromyalgia by Serrat et al. [70], a study by McCrae et al. [71] showed the opposite results with no improvement in pain management. The CBT use seems to be reasonable in terms of palliative care pain treatment and other symptom management in most patients. However, the level of evidence regarding efficiency varies. Comparison of studies on CBT and chronic pain is impeded by the use of different pain scales, aetiology of the pain, methods used in therapy, frequency and duration of the therapy, and time of the follow-ups. Therefore, the utility of this method should be carefully considered in every case due to the limited availability of qualified personnel.

### Physical exercise

The commonly advised method in any disease prevention is physical exercise. Borisovskaya et al. [72] described many probable mechanisms behind physical exercise's analgesic effect. According to the neuromatrix theory, chronic pain is a result of the central nervous system's structural maladaptation to constant stressful stimuli, including pain [63]. The plasticity of the nervous system allows for those changes to be reversed, by providing frequent positive stimuli, like physical exercise, over-riding negative input. Studies have shown that consistency is much more important than intensity or duration of physical training in achieving better pain management [72, 73]. It has been suggested by Geneen et al. [74] that long-term application of physical exercise regimen may be more effective.

Another mechanism of action involves restoring the balance between inflammatory and anti-inflammatory factors. Physical exercise reduces inflammation, which has been proven to ease the chronic pain [72, 75]. A study on a group of 126 women suffering from breast cancer who underwent mastectomy, showed that adequate physical activity reduced the pain experienced in the post-mastectomy pain syndrome and also correlated with the reduction of inflammation markers such as IL-6, IL-8, tumour necrosis factor and CRP [76].

A commonly known phenomenon of exercise-induced endogenous opioid secretion, could also contribute to physical exercise's analgesic effect [74, 75, 77]. However, the process may be disrupted in patients suffering from chronic diseases such as fibromyalgia [72, 75, 78, 79], deeming the treatment ineffective. Therefore, it is worth remembering that not every patient may benefit from adding exercise to the pain

management regimen. Apart from endogenous opioids, physical activity promotes the secretion of other neurotransmitters with analgesic effects such as serotonin [72, 75], dopamine and norepinephrine [72, 80].

Some patients may experience kinesiphobia due to fear of pain exacerbation during exercise. It is important to give the patient time to learn their safe, pain-free range of motion and to adjust the training's intensity gradually, under medical supervision [72, 81] and with the patient's consent [72, 73, 82]. A randomized controlled trial comparing manual therapy and therapeutic exercise in the treatment of non-specific chronic neck pain showed that patients with certain disorders may need many different types of exercise included in the training plan to achieve the best analgesic effect possible. Both methods were proven to be statistically significant in reducing pain. However, the therapeutic exercise group regained cervical mobility faster and the manual therapy group achieved pain relief first, suggesting that both methods combined should bring the best clinical results [83].

Despite many limitations of analysed studies, including lack of blinding of the intervention/therapist, different times of follow-up, not including all coexisting factors potentially altering the pain intensity (such as diet, analgesic or anti-inflammatory drugs, other chronic diseases), the clinical application of physical exercises in pain management and reducing disability was statistically significant compared to no intervention at all, education or pharmacological treatment only [84]. The great benefits of regular exercise (irrespective of its intensity or duration) to a patient's overall health, physical fitness and pain control support the recommendation of adopting physical activity as a part of chronic pain treatment [73, 85, 86].

It may improve sleep quality and subsequently lower pain sensitivity (poor sleep enhances the risk of higher pain sensitivity) [87, 88]. This method seems to be more effective in the reduction of musculoskeletal or diffuse rather than neuropathic pain phenotype. In addition, the exercise treatment should be adjusted to specific diseases [2]. For example, pain improvement with the use of exercises was confirmed in fibromyalgia and cancer patients [89, 90]. However, there is still a need for further research on the effectiveness of physical therapy in reducing chronic pain present in specific types of cancer and detailed guidelines for prescribing physical exercises in chronic pain control is emphasized in many studies [73, 91].

### **Biofeedback**

Another tested pain treatment modality is a method named biofeedback. It is an instrument-based

learning process, where an autonomic and neuromuscular activity is measured and visual, acoustic, or verbal feedback is provided, to promote self-control over physiological processes, which are otherwise outside awareness or under less voluntary control [92]. The method is based on the training of psychological responding and may be divided depending on the type of signal on different variants such as electromyography electrodermal activity, skin temperature, heart rate variability (HRV), respiratory of end-tidal CO<sub>2</sub>, and electroencephalography (EEG) biofeedback. There is also a modality with the use of functional magnetic resonance imaging and blood-oxygen-level dependent method [93].

The randomized controlled trial of neurofeedback (EEG) by Prinsloo et al. [94] in a group of 71 cancer survivors suffering from chemotherapy-induced peripheral neuropathy compared patients who underwent 20 sessions of EEG-biofeedback as a control group. Interestingly, a significant decrease in the worst pain, average pain and pain interference was confirmed in the EEG biofeedback group. In addition, neurological changes in the cortical location and the bandwidth targeted by intervention and differences in EEG activity were observed and considered predictive of symptom reduction [94]. The impact of HRV biofeedback was investigated in irritable bowel syndrome (IBS) and functional abdominal pain (FAP) in the pediatric setting [95]. 69.2% of patients with IBS declared full remission and 30.8% partial remission of the disease, whereas patients with FAP reported full remission in 63.6% of cases and partial remission in 36.4% of cases [95]. A pilot study of HRV biofeedback therapy for children and adolescents with chronic pain also showed promising results [96]. In the group of 21 patients' significant reduction of self-reported pain intensity and higher levels of self-reported school functioning were confirmed. In addition, the control patients in the waitlist group noted enhanced pain intensity during the waiting period [96]. Taking into consideration these promising results in adult and pediatric populations, different modalities of biofeedback ought to be tested in the palliative care setting. Further clinical trials with a higher number of enrolled participants should determine the future of this relatively simple and cost-effective method.

### **Acupuncture**

Acupuncture is an old Chinese technique that nowadays is one of the alternative pain management options available to patients. In ancient China, it was believed that every illness was caused by an imbalance in the Qi energy circulating in the human body and that by inserting needles into specific points on the

body (acupoints) the energy flow in meridian to which the targeted point belongs would be restored [97].

Studies show that it can have an analgesic effect and lower the dosage of analgesics needed to alleviate pain [98, 99]. There are several theories of the mechanism behind acupuncture. The first one argues that acupuncture stimulates the central nervous system and causes endorphins to release [100, 101]. Acupuncture was reported to elevate levels of  $\beta$ -endorphin, met-enkephalin and dynorphins in cerebrospinal fluid [97, 101]. The analgesic effect can be maximized if D-phenylalanine (inhibitor of enkephalinase) is administered before acupuncture [101]. The analgesic effect is achieved after a while, lasts a period and reaches areas different than the acupuncture was performed on, supporting the neuro-modulation theory [97, 101]. It was observed that naloxone reverses the effect of acupuncture [97, 100], giving the grounds for a theory about acupuncture regulating the expression of opioid production [101]. A study of acupuncture on rats showed an increased dopamine release in the striatum, supporting a theory that acupuncture modulates pain *via* monoamine release [100]. The involvement of noradrenergic and serotonergic pathways is another area of study [101] due to serotonin and oxytocin secretion following acupuncture [101–103]. The anti-inflammatory effect of ST36 point electroacupuncture has been researched on the model of breast tumours in mice [102]. The ST36 point is located on the anterior surface of the lower limb, its electrostimulation caused a reduction of IL-1 $\beta$ , TNF- $\alpha$  (inflammatory agents) and an increase of IL-10 (anti-inflammatory agent) in the serum and the tumour tissue, lowered the expression of Arg-1 and COX-2 protein that take part in suppression of T cells and NK cells function [102].

There are different types of acupuncture used. The first one is traditional acupuncture performed by insertion of the needle. In electroacupuncture after the insertion of the needle, an electric current is delivered through it. Other types of different stimuli are used on the acupoint instead of a needle — pressure in acupressure, electric stimulation in TEAS, heat in moxibustion or laser energy. Electroacupuncture is the most effective among them [98, 103]. Studies on acupuncture focus on finding areas for its clinical application. There are clinical trials researching the usage of acupuncture in perioperative and postoperative treatment [98, 104, 105], chronic pain management [106], depression [107], irritable bowel syndrome [108], fibromyalgia [109], rheumatoid arthritis [98], neuropathy [110, 111]. A study on 107 patients showed that the group of patients who received epidural analgesia and acupuncture reported significantly

better pain management scoring low on pain scales (postoperatively on the day of operation and two days after) than the control group who received epidural analgesia only [98, 104]. Acupuncture also lowered the dosage of opioids needed to uphold the analgesic effect [98, 104]. In another trial, focused on the recovery of 81 gastric cancer patients after surgery, the test group, which received transcutaneous electrical acupoint stimulation (TEAS), reported lower pain and regained gastrointestinal peristalsis faster [105]. The application of acupuncture is also researched in pain relief for cancer patients [112].

The USA National Comprehensive Cancer Network (NCCN) guidelines listed acupuncture as one of the alternative methods that can be used as a supplementation treatment when a patient experiences neuropathic pain, arthralgia or myalgia [99, 113–115]. The Society for Integrative Oncology in ASCO Guidelines recommends (moderate strength of the recommendation) acupuncture to patients suffering from joint pain after aromatase-inhibitor therapy in breast cancer survivors; general pain or musculoskeletal pain caused by cancer; and pain during systemic cancer therapy. The strength of recommendation for acupuncture for patients with chemotherapy-induced peripheral neuropathy and patients undergoing cancer surgery or other invasive procedures is weak [116]. Nevertheless, some studies reported that acupuncture reduces taxane-induced peripheral neuropathy (tingling, numbness, pain in distal extremities) and overall well-being [110, 111].

It is uncertain how much the placebo effect contributes to acupuncture's effectiveness. There was a study that compared positron emission tomography [with ( $^{11}\text{C}$ )–carfentanil] images of patients who received acupuncture and patients who received sham acupuncture, before and after 4 weeks of acupuncture treatment [117]. Short and long-term effect of increased mu-opioid receptors binding potential was only observed after real acupuncture [117]. An interesting point was made in a cross-cultural study which measured brain activity in patients in the USA and patients in China who received acupuncture or sham acupuncture [118]. A strong placebo effect was noticed in patients from the USA as the difference between real and sham acupuncture in brain activity was small [118]. In Chinese patients, the difference was more significant [118]. Even though the study was carried out on a small group of patients it brought to attention the impact of patients' cultural background. The placebo effect gives pain relief instantly, contrary to the maximal analgesic effect of acupuncture which is reached up to 24 h [97].

To sum up, the research on acupuncture effectiveness is still controversial as it lacks standardization,

Table 1. Key aspects of new directions in pain management in palliative care patients

Method	Possible mechanism	Conclusions
<b>Medical cannabis and cannabinoids</b>	<ul style="list-style-type: none"> <li>Increasing the amount of CB2 receptors on peripheral cells</li> <li>"Entourage effect"</li> </ul>	May be considered a part of pain management, especially in cases with a neuropathic component
<b>Music therapy</b>	<ul style="list-style-type: none"> <li>Reduction of cortisol</li> <li>Lower mean heart rate</li> </ul>	May provide higher spiritual well-being and lower distress
<b>Cognitive behavioural therapy</b>	Downregulation of IL-6	The utility of this method should be carefully considered in every case due to the limited availability of qualified personnel
<b>Physical exercise</b>	Improve sleep quality and subsequently lower pain sensitivity	This method seems to be more effective in the reduction of musculoskeletal or diffuse rather than neuropathic pain phenotype
<b>Biofeedback</b>	Promote self-control over physiological processes, which are otherwise outside awareness or under less voluntary control	Promising results in adult and paediatric populations, different modalities of biofeedback ought to be tested. Further clinical trials with a higher number of enrolled participants should determine the future of this relatively simple and cost-effective method
<b>Acupuncture</b>	<ul style="list-style-type: none"> <li>Stimulation of the central nervous system</li> <li>Endorphin release</li> <li>Regulating expression of opioid production</li> </ul>	The research on acupuncture effectiveness is still controversial as it lacks standardization, leading to contradicting results. The need of further research concerning the effectiveness and long-term application of acupuncture is needed. Overall, acupuncture is perceived as a complementary method of pharmacological pain management beneficial to patients' quality of life and well-being

leading to various, often contradicting results [119]. There are also discrepancies in establishing a credible control group. In sham acupuncture, the skin is not penetrated, but the point where the pressure is applied can be an actual acupoint or sham point. The need for further research concerning the effectiveness and long-term application of acupuncture is mentioned in many articles [116, 117, 119–121]. A summary of the main conclusions is demonstrated in Table 1. Additionally, information about ongoing and completed clinical trials is available as supplementary material (Supplementary Table 1).

## Conclusions

The complexity of pain necessitates a multifaceted approach for its effective management, which should not be limited to pharmacology and the use of analgesics. There is a need to explore diverse strategies and incorporate new and innovative methods. In this review cannabinoids and non-pharmacological methods of pain management, were discussed. There are currently plenty of alternative methods and mechanisms behind their analgesic and co-analgesic effects that might contribute to maximizing the effect of pain management strategies. However, the existing research studies do not provide conclusive evidence regarding their effectiveness. Therefore, these methods

may be considered with caution, in combination with evidence-based, standard methods to finally determine their efficiency in clinical practice.

## Article information and declarations

### Acknowledgements

None.

### Author contributions

GŁ, MG, and BKS designed the work. GŁ, MG, ZB, OS, and BKS analysed and interpreted data, drafted the work and wrote the manuscript. BKS supervised the manuscript. All authors approved the final version for publication and have agreed to be accountable for all aspects of the work.

### Conflict of interest

The authors declare no conflict of interest.

### Funding

The authors received no financial support for the research, authorship, and publication of this article.

### Supplementary material

The supplementary material for this article can be found online at [https://journals.viamedica.pl/palliative\\_medicine\\_in\\_practice/article/view/98210](https://journals.viamedica.pl/palliative_medicine_in_practice/article/view/98210).



## References

- Henschke N, Kamper SJ, Maher CG. The epidemiology and economic consequences of pain. *Mayo Clin Proc.* 2015; 90(1): 139–147, doi: [10.1016/j.mayocp.2014.09.010](https://doi.org/10.1016/j.mayocp.2014.09.010), indexed in Pubmed: 25572198.
- Cohen SP, Vase L, Hooten WM. Chronic pain: an update on burden, best practices, and new advances. *Lancet.* 2021; 397(10289): 2082–2097, doi: [10.1016/S0140-6736\(21\)00393-7](https://doi.org/10.1016/S0140-6736(21)00393-7), indexed in Pubmed: 34062143.
- Steglitz J, Buscemi J, Ferguson MJ. The future of pain research, education, and treatment: a summary of the IOM report “Relieving pain in America: a blueprint for transforming prevention, care, education, and research”. *Transl Behav Med.* 2012; 2(1): 6–8, doi: [10.1007/s13142-012-0110-2](https://doi.org/10.1007/s13142-012-0110-2), indexed in Pubmed: 24073092.
- Gaskin DJ, Richard P. The economic costs of pain in the United States. *J Pain.* 2012; 13(8): 715–724, doi: [10.1016/j.jpain.2012.03.009](https://doi.org/10.1016/j.jpain.2012.03.009), indexed in Pubmed: 22607834.
- Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. *Eur J Pain.* 2006; 10(4): 287–333, doi: [10.1016/j.ejpain.2005.06.009](https://doi.org/10.1016/j.ejpain.2005.06.009), indexed in Pubmed: 16095934.
- Michaelides A, Zis P. Depression, anxiety and acute pain: links and management challenges. *Postgrad Med.* 2019; 131(7): 438–444, doi: [10.1080/00325481.2019.1663705](https://doi.org/10.1080/00325481.2019.1663705), indexed in Pubmed: 31482756.
- Wilkie DJ, Ezenwa MO. Pain and symptom management in palliative care and at end of life. *Nurs Outlook.* 2012; 60(6): 357–364, doi: [10.1016/j.outlook.2012.08.002](https://doi.org/10.1016/j.outlook.2012.08.002), indexed in Pubmed: 22985972.
- Henson LA, Maddocks M, Evans C, et al. Palliative care and the management of common distressing symptoms in advanced cancer: pain, breathlessness, nausea and vomiting, and fatigue. *J Clin Oncol.* 2020; 38(9): 905–914, doi: [10.1200/JCO.19.00470](https://doi.org/10.1200/JCO.19.00470), indexed in Pubmed: 32023162.
- Alexander K, Goldberg J, Korc-Grodzicki B. Palliative care and symptom management in older patients with cancer. *Clin Geriatr Med.* 2016; 32(1): 45–62, doi: [10.1016/j.cger.2015.08.004](https://doi.org/10.1016/j.cger.2015.08.004), indexed in Pubmed: 26614860.
- Williams N, Hermans K, Cohen J, et al. Prognosis does not change the landscape: palliative home care clients experience high rates of pain and nausea, regardless of prognosis. *BMC Palliat Care.* 2021; 20(1): 165, doi: [10.1186/s12904-021-00851-x](https://doi.org/10.1186/s12904-021-00851-x), indexed in Pubmed: 34666732.
- Yoon SL, Scarton L, Duckworth L, et al. Pain, symptom distress, and pain barriers by age among patients with cancer receiving hospice care: Comparison of baseline data. *J Geriatr Oncol.* 2021; 12(7): 1068–1075, doi: [10.1016/j.jgo.2021.04.008](https://doi.org/10.1016/j.jgo.2021.04.008), indexed in Pubmed: 33967022.
- Corli O, Pellegrini G, Bosetti C, et al. Impact of palliative care in evaluating and relieving symptoms in patients with advanced cancer. Results from the DEMETRA study. *Int J Environ Res Public Health.* 2020; 17(22), doi: [10.3390/ijerph17228429](https://doi.org/10.3390/ijerph17228429), indexed in Pubmed: 33202542.
- Kong H, Liu Y, Wu K, et al. Pain and self-management status among chinese patients with cancer during the COVID-19 pandemic. *Pain Manag Nurs.* 2022; 23(1): 26–30, doi: [10.1016/j.pmn.2021.09.004](https://doi.org/10.1016/j.pmn.2021.09.004), indexed in Pubmed: 34756521.
- Dy SM, Isenberg SR, Al Hamayel NA. Palliative care for cancer survivors. *Med Clin North Am.* 2017; 101(6): 1181–1196, doi: [10.1016/j.mcna.2017.06.009](https://doi.org/10.1016/j.mcna.2017.06.009), indexed in Pubmed: 28992862.
- MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. *Eur J Intern Med.* 2018; 49: 12–19, doi: [10.1016/j.ejim.2018.01.004](https://doi.org/10.1016/j.ejim.2018.01.004), indexed in Pubmed: 29307505.
- Anand U, Pacchetti B, Anand P, et al. Cannabis-based medicines and pain: a review of potential synergistic and entourage effects. *Pain Manag.* 2021; 11(4): 395–403, doi: [10.2217/pmt-2020-0110](https://doi.org/10.2217/pmt-2020-0110), indexed in Pubmed: 33703917.
- Verhamme KMC, Bohnen AM. Are we facing an opioid crisis in Europe? *Lancet Public Health.* 2019; 4(10): e483–e484, doi: [10.1016/S2468-2667\(19\)30156-2](https://doi.org/10.1016/S2468-2667(19)30156-2), indexed in Pubmed: 31444002.
- van den Hoogen NJ, Harding EK, Davidson CED, et al. Cannabinoids in chronic pain: therapeutic potential through microglia modulation. *Front Neural Circuits.* 2021; 15: 816747, doi: [10.3389/fncir.2021.816747](https://doi.org/10.3389/fncir.2021.816747), indexed in Pubmed: 35069129.
- Brown MRD, Farquhar-Smith WP. Cannabinoids and cancer pain: a new hope or a false dawn? *Eur J Intern Med.* 2018; 49: 30–36, doi: [10.1016/j.ejim.2018.01.020](https://doi.org/10.1016/j.ejim.2018.01.020), indexed in Pubmed: 29482740.
- Blanton HL, Brelsfoard J, DeTurk N, et al. Cannabinoids: current and future options to treat chronic and chemotherapy-induced neuropathic pain. *Drugs.* 2019; 79(9): 969–995, doi: [10.1007/s40265-019-01132-x](https://doi.org/10.1007/s40265-019-01132-x), indexed in Pubmed: 31127530.
- Chung M, Kim HK, Abdi S. Update on cannabis and cannabinoids for cancer pain. *Curr Opin Anaesthesiol.* 2020; 33(6): 825–831, doi: [10.1097/ACO.0000000000000934](https://doi.org/10.1097/ACO.0000000000000934), indexed in Pubmed: 33110020.
- Wang Li, Hong PJ, May C, et al. Medical cannabis or cannabinoids for chronic non-cancer and cancer related pain: a systematic review and meta-analysis of randomised clinical trials. *BMJ.* 2021; 374(n1034): 2448–2460, doi: [10.1136/bmj.n1034](https://doi.org/10.1136/bmj.n1034), indexed in Pubmed: 34497047.
- Sihota A, Smith BK, Ahmed SA, et al. Consensus-based recommendations for titrating cannabinoids and tapering opioids for chronic pain control. *Int J Clin Pract.* 2021; 75(8): e13871, doi: [10.1111/ijcp.13871](https://doi.org/10.1111/ijcp.13871), indexed in Pubmed: 33249713.
- Capano A, Weaver R, Burkman E. Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study. *Postgrad Med.* 2020; 132(1): 56–61, doi: [10.1080/00325481.2019.1685298](https://doi.org/10.1080/00325481.2019.1685298), indexed in Pubmed: 31711352.
- Johnson JR, Burnell-Nugent M, Lossignol D, et al. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. *J Pain Symptom Manage.* 2010; 39(2): 167–179, doi: [10.1016/j.jpainsymman.2009.06.008](https://doi.org/10.1016/j.jpainsymman.2009.06.008), indexed in Pubmed: 19896326.
- De Aquino JP, Meyerovich J, Xie CZ, et al. Delta-9-tetrahydrocannabinol modulates pain sensitivity among persons receiving opioid agonist therapy for opioid use disorder: A within-subject, randomized, placebo-controlled laboratory study. *Addict Biol.* 2023; 28(9): e13317, doi: [10.1111/adb.13317](https://doi.org/10.1111/adb.13317), indexed in Pubmed: 37644897.
- De Vita MJ, Moskal D, Maisto SA, et al. Association of cannabinoid administration with experimental pain in healthy adults: a systematic review and meta-analysis. *JAMA Psychiatry.* 2018; 75(11): 1118–1127, doi: [10.1001/jamapsychiatry.2018.2503](https://doi.org/10.1001/jamapsychiatry.2018.2503), indexed in Pubmed: 30422266.
- Lake S, Socías ME, Milloy MJ. Evidence shows that cannabis has fewer relative harms than opioids. *CMAJ.* 2020; 192(7): E166–E167, doi: [10.1503/cmaj.74120](https://doi.org/10.1503/cmaj.74120), indexed in Pubmed: 32071110.
- Campbell CM, Mun CJ, Hamilton KR, et al. Within-subject, double-blind, randomized, placebo-controlled

- evaluation of combining the cannabinoid dronabinol and the opioid hydromorphone in adults with chronic pain. *Neuropsychopharmacology*. 2023; 48(11): 1630–1638, doi: [10.1038/s41386-023-01597-1](https://doi.org/10.1038/s41386-023-01597-1), indexed in Pubmed: [37202479](https://pubmed.ncbi.nlm.nih.gov/37202479/).
30. Nielsen S, Picco L, Murnion B, et al. Opioid-sparing effect of medical cannabinoids for analgesia: an updated systematic review and meta-analysis of preclinical and clinical studies. *Neuropsychopharmacology*. 2022; 47(7): 1315–1330, doi: [10.1038/s41386-022-01322-4](https://doi.org/10.1038/s41386-022-01322-4), indexed in Pubmed: [35459926](https://pubmed.ncbi.nlm.nih.gov/35459926/).
  31. Noori A, Miroshnychenko A, Shergill Y, et al. Opioid-sparing effects of medical cannabis or cannabinoids for chronic pain: a systematic review and meta-analysis of randomised and observational studies. *BMJ Open*. 2021; 11(7): e047717, doi: [10.1136/bmjopen-2020-047717](https://doi.org/10.1136/bmjopen-2020-047717), indexed in Pubmed: [34321302](https://pubmed.ncbi.nlm.nih.gov/34321302/).
  32. McParland AL, Bhatia A, Matelski J, et al. Evaluating the impact of cannabinoids on sleep health and pain in patients with chronic neuropathic pain: a systematic review and meta-analysis of randomized controlled trials. *Reg Anesth Pain Med*. 2023; 48(4): 180–190, doi: [10.1136/rapm-2021-103431](https://doi.org/10.1136/rapm-2021-103431), indexed in Pubmed: [36598058](https://pubmed.ncbi.nlm.nih.gov/36598058/).
  33. Zubcevic K, Petersen M, Bach FW, et al. Oral capsules of tetra-hydro-cannabinol (THC), cannabidiol (CBD) and their combination in peripheral neuropathic pain treatment. *Eur J Pain*. 2023; 27(4): 492–506, doi: [10.1002/ejp.2072](https://doi.org/10.1002/ejp.2072), indexed in Pubmed: [36571471](https://pubmed.ncbi.nlm.nih.gov/36571471/).
  34. Barakji J, Korang SK, Feinberg J, et al. Cannabinoids versus placebo for pain: a systematic review with meta-analysis and trial sequential analysis. *PLoS One*. 2023; 18(1): e0267420, doi: [10.1371/journal.pone.0267420](https://doi.org/10.1371/journal.pone.0267420), indexed in Pubmed: [36716312](https://pubmed.ncbi.nlm.nih.gov/36716312/).
  35. Zeraatkar D, Cooper MA, Agarwal A, et al. Long-term and serious harms of medical cannabis and cannabinoids for chronic pain: a systematic review of non-randomised studies. *BMJ Open*. 2022; 12(8): e054282, doi: [10.1136/bmjopen-2021-054282](https://doi.org/10.1136/bmjopen-2021-054282), indexed in Pubmed: [35926992](https://pubmed.ncbi.nlm.nih.gov/35926992/).
  36. Bilbao A, Spanagel R. Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. *BMC Med*. 2022; 20(1): 259, doi: [10.1186/s12916-022-02459-1](https://doi.org/10.1186/s12916-022-02459-1), indexed in Pubmed: [35982439](https://pubmed.ncbi.nlm.nih.gov/35982439/).
  37. van Orten-Luiten ACB, de Roos NM, Majait S, et al. Effects of cannabidiol chewing gum on perceived pain and well-being of irritable bowel syndrome patients: a placebo-controlled crossover exploratory intervention study with symptom-driven dosing. *Cannabis Cannabinoid Res*. 2022; 7(4): 436–444, doi: [10.1089/can.2020.0087](https://doi.org/10.1089/can.2020.0087), indexed in Pubmed: [33998882](https://pubmed.ncbi.nlm.nih.gov/33998882/).
  38. Doeve BH, van de Meeberg MM, van Schaik FDM, et al. A systematic review with meta-analysis of the efficacy of cannabis and cannabinoids for inflammatory bowel disease: what can we learn from randomized and non-randomized studies? *J Clin Gastroenterol*. 2021; 55(9): 798–809, doi: [10.1097/MCG.0000000000001393](https://doi.org/10.1097/MCG.0000000000001393), indexed in Pubmed: [32675631](https://pubmed.ncbi.nlm.nih.gov/32675631/).
  39. Chang L, Cash BD, Lembo A, et al. Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: Results from a phase 2b randomized placebo-controlled trial (CAPTIVATE). *Neurogastroenterol Motil*. 2023; 35(5): e14539, doi: [10.1111/nmo.14539](https://doi.org/10.1111/nmo.14539), indexed in Pubmed: [36740814](https://pubmed.ncbi.nlm.nih.gov/36740814/).
  40. Abrams DI, Couey P, Dixit N, et al. Effect of inhaled cannabis for pain in adults with sickle cell disease: a randomized clinical trial. *JAMA Netw Open*. 2020; 3(7): e2010874, doi: [10.1001/jamanetworkopen.2020.10874](https://doi.org/10.1001/jamanetworkopen.2020.10874), indexed in Pubmed: [32678452](https://pubmed.ncbi.nlm.nih.gov/32678452/).
  41. Vecchio D, Varrasi C, Virgilio E, et al. Cannabinoids in multiple sclerosis: a neurophysiological analysis. *Acta Neurol Scand*. 2020; 142(4): 333–338, doi: [10.1111/ane.13313](https://doi.org/10.1111/ane.13313), indexed in Pubmed: [32632918](https://pubmed.ncbi.nlm.nih.gov/32632918/).
  42. Russo M, Naro A, Leo A, et al. Evaluating Sativex® in neuropathic pain management: a clinical and neurophysiological assessment in multiple sclerosis. *Pain Med*. 2016; 17(6): 1145–1154, doi: [10.1093/pm/pnv080](https://doi.org/10.1093/pm/pnv080), indexed in Pubmed: [26764336](https://pubmed.ncbi.nlm.nih.gov/26764336/).
  43. van de Donk T, Niesters M, Kowal MA, et al. An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia. *Pain*. 2019; 160(4): 860–869, doi: [10.1097/j.pain.0000000000001464](https://doi.org/10.1097/j.pain.0000000000001464), indexed in Pubmed: [30585986](https://pubmed.ncbi.nlm.nih.gov/30585986/).
  44. de Vries M, van Rijckevorsel DCM, Vissers KCP, et al. Tetrahydrocannabinol does not reduce pain in patients with chronic abdominal pain in a phase 2 placebo-controlled study. *Clin Gastroenterol Hepatol*. 2017; 15(7): 1079–1086.e4, doi: [10.1016/j.cgh.2016.09.147](https://doi.org/10.1016/j.cgh.2016.09.147), indexed in Pubmed: [27720917](https://pubmed.ncbi.nlm.nih.gov/27720917/).
  45. Hoggart B, Ratcliffe S, Ehler E, et al. A multicentre, open-label, follow-on study to assess the long-term maintenance of effect, tolerance and safety of THC/CBD oromucosal spray in the management of neuropathic pain. *J Neurol*. 2015; 262(1): 27–40, doi: [10.1007/s00415-014-7502-9](https://doi.org/10.1007/s00415-014-7502-9), indexed in Pubmed: [25270679](https://pubmed.ncbi.nlm.nih.gov/25270679/).
  46. Serpell M, Ratcliffe S, Hovorka J, et al. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. *Eur J Pain*. 2014; 18(7): 999–1012, doi: [10.1002/j.1532-2149.2013.00445.x](https://doi.org/10.1002/j.1532-2149.2013.00445.x), indexed in Pubmed: [24420962](https://pubmed.ncbi.nlm.nih.gov/24420962/).
  47. Wallace MS, Marcotte TD, Atkinson JH, et al. A secondary analysis from a randomized trial on the effect of plasma tetrahydrocannabinol levels on pain reduction in painful diabetic peripheral neuropathy. *J Pain*. 2020; 21(11-12): 1175–1186, doi: [10.1016/j.jpain.2020.03.003](https://doi.org/10.1016/j.jpain.2020.03.003), indexed in Pubmed: [32565122](https://pubmed.ncbi.nlm.nih.gov/32565122/).
  48. Almog S, Aharon-Peretz J, Vulfsons S, et al. The pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: A randomized, double-blinded, placebo-controlled trial. *Eur J Pain*. 2020; 24(8): 1505–1516, doi: [10.1002/ejp.1605](https://doi.org/10.1002/ejp.1605), indexed in Pubmed: [32445190](https://pubmed.ncbi.nlm.nih.gov/32445190/).
  49. Bialas P, Fitzcharles MA, Klose P, et al. Long-term observational studies with cannabis-based medicines for chronic non-cancer pain: a systematic review and meta-analysis of effectiveness and safety. *Eur J Pain*. 2022; 26(6): 1221–1233, doi: [10.1002/ejp.1957](https://doi.org/10.1002/ejp.1957), indexed in Pubmed: [35467781](https://pubmed.ncbi.nlm.nih.gov/35467781/).
  50. Gedin F, Blomé S, Pontén M, et al. Placebo response and media attention in randomized clinical trials assessing cannabis-based therapies for pain: a systematic review and meta-analysis. *JAMA Netw Open*. 2022; 5(11): e2243848, doi: [10.1001/jamanetworkopen.2022.43848](https://doi.org/10.1001/jamanetworkopen.2022.43848), indexed in Pubmed: [36441553](https://pubmed.ncbi.nlm.nih.gov/36441553/).
  51. Dieterle M, Zurbriggen L, Mauermann E, et al. Pain response to cannabidiol in opioid-induced hyperalgesia, acute nociceptive pain, and allodynia using a model mimicking acute pain in healthy adults in a randomized trial (CANAB II). *Pain*. 2022; 163(10): 1919–1928, doi: [10.1097/j.pain.0000000000002591](https://doi.org/10.1097/j.pain.0000000000002591), indexed in Pubmed: [35239547](https://pubmed.ncbi.nlm.nih.gov/35239547/).
  52. Garza-Villarreal EA, Pando V, Vuust P, et al. Music-induced analgesia in chronic pain conditions: a systematic review and meta-analysis. *Pain Physician*. 2017; 20(7): 597–610, indexed in Pubmed: [29149141](https://pubmed.ncbi.nlm.nih.gov/29149141/).

53. Goksan S, Baxter L, Moultrie F, et al. The influence of the descending pain modulatory system on infant pain-related brain activity. *Elife*. 2018; 11(7), doi: [10.7554/eLife.37125](https://doi.org/10.7554/eLife.37125), indexed in Pubmed: [30201093](https://pubmed.ncbi.nlm.nih.gov/30201093/).
54. Lin CL, Hwang SL, Jiang P, et al. Effect of music therapy on pain after orthopedic surgery—a systematic review and meta-analysis. *Pain Pract*. 2020; 20(4): 422–436, doi: [10.1111/papr.12864](https://doi.org/10.1111/papr.12864), indexed in Pubmed: [31785131](https://pubmed.ncbi.nlm.nih.gov/31785131/).
55. Huang E, Huang J. Music therapy: a noninvasive treatment to reduce anxiety and pain of colorectal cancer patients—a systemic literature review. *Medicina (Kaunas)*. 2023; 59(3), doi: [10.3390/medicina59030482](https://doi.org/10.3390/medicina59030482), indexed in Pubmed: [36984483](https://pubmed.ncbi.nlm.nih.gov/36984483/).
56. Tang H, Chen L, Wang Y, et al. The efficacy of music therapy to relieve pain, anxiety, and promote sleep quality, in patients with small cell lung cancer receiving platinum-based chemotherapy. *Support Care Cancer*. 2021; 29(12): 7299–7306, doi: [10.1007/s00520-021-06152-6](https://doi.org/10.1007/s00520-021-06152-6), indexed in Pubmed: [34041615](https://pubmed.ncbi.nlm.nih.gov/34041615/).
57. Warth M, Keßler J, Hillecke TK, et al. Music therapy in palliative care. *Dtsch Arztebl Int*. 2015; 112(46): 788–794, doi: [10.3238/arztebl.2015.0788](https://doi.org/10.3238/arztebl.2015.0788), indexed in Pubmed: [26806566](https://pubmed.ncbi.nlm.nih.gov/26806566/).
58. Lee JH, Lee JH. The effects of music on pain: a meta-analysis. *J Music Ther*. 2016; 53(4): 430–477, doi: [10.1093/jmt/thw012](https://doi.org/10.1093/jmt/thw012), indexed in Pubmed: [27760797](https://pubmed.ncbi.nlm.nih.gov/27760797/).
59. Gutsell KJo, Schluchter M, Margevicius S, et al. Music therapy reduces pain in palliative care patients: a randomized controlled trial. *J Pain Symptom Manage*. 2013; 45(5): 822–831, doi: [10.1016/j.jpainsymman.2012.05.008](https://doi.org/10.1016/j.jpainsymman.2012.05.008), indexed in Pubmed: [23017609](https://pubmed.ncbi.nlm.nih.gov/23017609/).
60. Li Y, Xing X, Shi X, et al. The effectiveness of music therapy for patients with cancer: A systematic review and meta-analysis. *J Adv Nurs*. 2020; 76(5): 1111–1123, doi: [10.1111/jan.14313](https://doi.org/10.1111/jan.14313), indexed in Pubmed: [32017183](https://pubmed.ncbi.nlm.nih.gov/32017183/).
61. Koehler F, Kessler J, Stoffel M, et al. Psychoneuroendocrinological effects of music therapy versus mindfulness in palliative care: results from the ‘Song of Life’ randomized controlled trial. *Support Care Cancer*. 2022; 30(1): 625–634, doi: [10.1007/s00520-021-06435-y](https://doi.org/10.1007/s00520-021-06435-y), indexed in Pubmed: [34355279](https://pubmed.ncbi.nlm.nih.gov/34355279/).
62. Knoerl R, Lavoie Smith EM, Weisberg J. Chronic pain and cognitive behavioral therapy: an integrative review. *West J Nurs Res*. 2016; 38(5): 596–628, doi: [10.1177/0193945915615869](https://doi.org/10.1177/0193945915615869), indexed in Pubmed: [26604219](https://pubmed.ncbi.nlm.nih.gov/26604219/).
63. Melzack R. From the gate to the neuromatrix. *Pain*. 1999; 82(Suppl 6): S121–S126, doi: [10.1016/S0304-3959\(99\)00145-1](https://doi.org/10.1016/S0304-3959(99)00145-1), indexed in Pubmed: [10491980](https://pubmed.ncbi.nlm.nih.gov/10491980/).
64. Seminowicz DA, Shpaner M, Keaser ML, et al. Cognitive-behavioral therapy increases prefrontal cortex gray matter in patients with chronic pain. *J Pain*. 2013; 14(12): 1573–1584, doi: [10.1016/j.jpain.2013.07.020](https://doi.org/10.1016/j.jpain.2013.07.020), indexed in Pubmed: [24135432](https://pubmed.ncbi.nlm.nih.gov/24135432/).
65. Saxena AK, Bhardwaj N, Chilkoti GT, et al. Modulation of mRNA expression of IL-6 and mTORC1 and efficacy and feasibility of an integrated approach encompassing cognitive behavioral therapy along with pregabalin for management of neuropathic pain in postherpetic neuralgia: a pilot study. *Pain Med*. 2021; 22(10): 2276–2282, doi: [10.1093/pm/pnab142](https://doi.org/10.1093/pm/pnab142), indexed in Pubmed: [34097069](https://pubmed.ncbi.nlm.nih.gov/34097069/).
66. Zhao YT, Deng J, Liu HM, et al. Adaptation of prefrontal cortex mediated by IL-6/STAT3/Acp5 pathway contributes to the comorbidity of neuropathic pain and depression in rats. *J Neuroinflammation*. 2022; 19(1): 144, doi: [10.1186/s12974-022-02503-0](https://doi.org/10.1186/s12974-022-02503-0), indexed in Pubmed: [35690777](https://pubmed.ncbi.nlm.nih.gov/35690777/).
67. Darnall BD, Roy A, Chen AL, et al. Comparison of a single-session pain management skills intervention with a single-session health education intervention and 8 sessions of cognitive behavioral therapy in adults with chronic low back pain: a randomized clinical trial. *JAMA Netw Open*. 2021; 4(8): e2113401, doi: [10.1001/jamanetworkopen.2021.13401](https://doi.org/10.1001/jamanetworkopen.2021.13401), indexed in Pubmed: [34398206](https://pubmed.ncbi.nlm.nih.gov/34398206/).
68. Rodin G, Malfitano C, Rydall A, et al. Emotion And Symptom-focused Engagement (EASE): a randomized phase II trial of an integrated psychological and palliative care intervention for patients with acute leukemia. *Support Care Cancer*. 2020; 28(1): 163–176, doi: [10.1007/s00520-019-04723-2](https://doi.org/10.1007/s00520-019-04723-2), indexed in Pubmed: [31001692](https://pubmed.ncbi.nlm.nih.gov/31001692/).
69. García-Dasí M, Pérez-Alenda S, Carrasco JJ, et al. Effects of a non-pharmacological approach for chronic pain management in patients with haemophilia: efficacy of cognitive-behavioural therapy associated with physiotherapy. *Haemophilia*. 2021; 27(3): e357–e367, doi: [10.1111/hae.14284](https://doi.org/10.1111/hae.14284), indexed in Pubmed: [33650767](https://pubmed.ncbi.nlm.nih.gov/33650767/).
70. Serrat M, Sanabria-Mazo JP, Almirall M, et al. Effectiveness of a multicomponent treatment based on pain neuroscience education, therapeutic exercise, cognitive behavioral therapy, and mindfulness in patients with fibromyalgia (FIBROWALK study): a randomized controlled trial. *Phys Ther*. 2021; 101(12), doi: [10.1093/ptj/pzab200](https://doi.org/10.1093/ptj/pzab200), indexed in Pubmed: [34499174](https://pubmed.ncbi.nlm.nih.gov/34499174/).
71. McCrae CS, Williams J, Roditi D, et al. Cognitive behavioral treatments for insomnia and pain in adults with comorbid chronic insomnia and fibromyalgia: clinical outcomes from the SPIN randomized controlled trial. *Sleep*. 2019; 42(3), doi: [10.1093/sleep/zsy234](https://doi.org/10.1093/sleep/zsy234), indexed in Pubmed: [30496533](https://pubmed.ncbi.nlm.nih.gov/30496533/).
72. Borisovskaya A, Chmelik E, Karnik A. Exercise and chronic pain. *Adv Exp Med Biol*. 2020; 1228: 233–253, doi: [10.1007/978-981-15-1792-1\\_16](https://doi.org/10.1007/978-981-15-1792-1_16), indexed in Pubmed: [32342462](https://pubmed.ncbi.nlm.nih.gov/32342462/).
73. Ambrose KR, Golightly YM. Physical exercise as non-pharmacological treatment of chronic pain: Why and when. *Best Pract Res Clin Rheumatol*. 2015; 29(1): 120–130, doi: [10.1016/j.berh.2015.04.022](https://doi.org/10.1016/j.berh.2015.04.022), indexed in Pubmed: [26267006](https://pubmed.ncbi.nlm.nih.gov/26267006/).
74. Geneen LJ, Moore RA, Clarke C, et al. Physical activity and exercise for chronic pain in adults: an overview of Cochrane Reviews. *Cochrane Database Syst Rev*. 2017; 1(1): CD011279, doi: [10.1002/14651858.CD011279.pub2](https://doi.org/10.1002/14651858.CD011279.pub2), indexed in Pubmed: [28087891](https://pubmed.ncbi.nlm.nih.gov/28087891/).
75. Sluka KA, Frey-Law L, Hoeger Bement M. Exercise-induced pain and analgesia? Underlying mechanisms and clinical translation. *Pain*. 2018; 159 Suppl 1(Suppl 1): S91–S97, doi: [10.1097/j.pain.0000000000001235](https://doi.org/10.1097/j.pain.0000000000001235), indexed in Pubmed: [30113953](https://pubmed.ncbi.nlm.nih.gov/30113953/).
76. Calapai M, Puzzo L, Bova G, et al. Effects of physical exercise and motor activity on oxidative stress and inflammation in post-mastectomy pain syndrome. *Antioxidants (Basel)*. 2023; 12(3), doi: [10.3390/antiox12030643](https://doi.org/10.3390/antiox12030643), indexed in Pubmed: [36978891](https://pubmed.ncbi.nlm.nih.gov/36978891/).
77. Naugle KM, Fillingim RB, Riley JL. A meta-analytic review of the hypoalgesic effects of exercise. *J Pain*. 2012; 13(12): 1139–1150, doi: [10.1016/j.jpain.2012.09.006](https://doi.org/10.1016/j.jpain.2012.09.006), indexed in Pubmed: [23141188](https://pubmed.ncbi.nlm.nih.gov/23141188/).
78. Daenen L, Varkey E, Kellmann M, et al. Exercise, not to exercise, or how to exercise in patients with chronic pain? Applying science to practice. *Clin J Pain*. 2015; 31(2): 108–114, doi: [10.1097/AJP.0000000000000099](https://doi.org/10.1097/AJP.0000000000000099), indexed in Pubmed: [24662498](https://pubmed.ncbi.nlm.nih.gov/24662498/).
79. Nijs Jo, Kosek E, Van Oosterwijck J, et al. Dysfunctional endogenous analgesia during exercise in patients with chronic pain: to exercise or not to exercise? *Pain Physician*. 2012; 15: ES205–ES213.

80. Aitken D, Buchbinder R, Jones G, et al. Interventions to improve adherence to exercise for chronic musculoskeletal pain in adults. *Aust Fam Physician*. 2015; 44(1-2): 39–42, indexed in Pubmed: [25688958](#).
81. Nijs Jo, Lluch Gírbés E, Lundberg M, et al. Exercise therapy for chronic musculoskeletal pain: Innovation by altering pain memories. *Man Ther*. 2015; 20(1): 216–220, doi: [10.1016/j.math.2014.07.004](#), indexed in Pubmed: [25090974](#).
82. Slade SC, Patel S, Underwood M, et al. What are patient beliefs and perceptions about exercise for non-specific chronic low back pain? A systematic review of qualitative studies. *Clin J Pain*. 2014; 30(11): 995–1005, doi: [10.1097/AJP.0000000000000044](#), indexed in Pubmed: [24300225](#).
83. Bernal-Utrera C, Gonzalez-Gerez JJ, Anarte-Lazo E, et al. Manual therapy versus therapeutic exercise in non-specific chronic neck pain: a randomized controlled trial. *Trials*. 2020; 21(1): 682, doi: [10.1186/s13063-020-04610-w](#), indexed in Pubmed: [32723399](#).
84. Fernández-Rodríguez R, Álvarez-Bueno C, Cavero-Redondo I, et al. Best exercise options for reducing pain and disability in adults with chronic low back pain: pilates, strength, core-based, and mind-body. A network meta-analysis. *J Orthop Sports Phys Ther*. 2022; 52(8): 505–521, doi: [10.2519/jospt.2022.10671](#), indexed in Pubmed: [35722759](#).
85. Yee J, Davis GM, Hackett D, et al. Physical activity for symptom management in women with metastatic breast cancer: a randomized feasibility trial on physical activity and breast metastases. *J Pain Symptom Manage*. 2019; 58(6): 929–939, doi: [10.1016/j.jpainsymman.2019.07.022](#), indexed in Pubmed: [31374368](#).
86. Klein I, Kalichman L, Chen N, et al. Effect of physical activity levels on oncological breast surgery recovery: a prospective cohort study. *Sci Rep*. 2021; 11(1): 10432, doi: [10.1038/s41598-021-89908-8](#), indexed in Pubmed: [34002007](#).
87. Zhu M, Huang H. The underlying mechanisms of sleep deprivation exacerbating neuropathic pain. *Nat Sci Sleep*. 2023; 15: 579–591, doi: [10.2147/NSS.S414174](#), indexed in Pubmed: [37533626](#).
88. Ding W, Yang L, Shi E, et al. The endocannabinoid N-arachidonoyl dopamine is critical for hyperalgesia induced by chronic sleep disruption. *Nat Commun*. 2023; 14(1): 6696, doi: [10.1038/s41467-023-42283-6](#), indexed in Pubmed: [37880241](#).
89. Izquierdo-Alventosa R, Inglés M, Cortés-Amador S, et al. Low-Intensity physical exercise improves pain catastrophizing and other psychological and physical aspects in women with fibromyalgia: a randomized controlled trial. *Int J Environ Res Public Health*. 2020; 17(10), doi: [10.3390/ijerph17103634](#), indexed in Pubmed: [32455853](#).
90. López-Sendín N, Alburquerque-Sendín F, Cleland JA, et al. Effects of physical therapy on pain and mood in patients with terminal cancer: a pilot randomized clinical trial. *J Altern Complement Med*. 2012; 18(5): 480–486, doi: [10.1089/acm.2011.0277](#), indexed in Pubmed: [22540970](#).
91. Barker K, Eickmeyer S. Therapeutic Exercise. *Med Clin North Am*. 2020; 104(2): 189–198, doi: [10.1016/j.mcna.2019.10.003](#), indexed in Pubmed: [32035563](#).
92. Wagner B, Steiner M, Huber DF, et al. The effect of biofeedback interventions on pain, overall symptoms, quality of life and physiological parameters in patients with pelvic pain: a systematic review. *Wien Klin Wochenschr*. 2022; 134(Suppl 1): 11–48, doi: [10.1007/s00508-021-01827-w](#), indexed in Pubmed: [33751183](#).
93. Tolin DF, Davies CD, Moskow DM, et al. Biofeedback and neurofeedback for anxiety disorders: a quantitative and qualitative systematic review. *Adv Exp Med Biol*. 2020; 1191: 265–289, doi: [10.1007/978-981-32-9705-0\\_16](#), indexed in Pubmed: [32002934](#).
94. Prinsloo S, Novy D, Driver L, et al. Randomized controlled trial of neurofeedback on chemotherapy-induced peripheral neuropathy: A pilot study. *Cancer*. 2017; 123(11): 1989–1997, doi: [10.1002/cncr.30649](#), indexed in Pubmed: [28257146](#).
95. Stern MJ, Guiles RAF, Gevirtz R. HRV biofeedback for pediatric irritable bowel syndrome and functional abdominal pain: a clinical replication series. *Appl Psychophysiol Biofeedback*. 2014; 39(3-4): 287–291, doi: [10.1007/s10484-014-9261-x](#), indexed in Pubmed: [25274501](#).
96. Yetwin AK, Mahrer NE, Bell TS, et al. Heart rate variability biofeedback therapy for children and adolescents with chronic pain: a pilot study. *J Pediatr Nurs*. 2022; 66: 151–159, doi: [10.1016/j.pedn.2022.06.008](#), indexed in Pubmed: [35777250](#).
97. Liao GS, Apaya MK, Shyur LF. Herbal medicine and acupuncture for breast cancer palliative care and adjuvant therapy. *Evid Based Complement Alternat Med*. 2013; 437948, doi: [10.1155/2013/437948](#), indexed in Pubmed: [23840256](#).
98. Vickers AJ, Vertosick EA, Lewith G, et al. Acupuncture for chronic pain: update of an individual patient data meta-analysis. *J Pain*. 2018; 19(5): 455–474, doi: [10.1016/j.jpain.2017.11.005](#), indexed in Pubmed: [29198932](#).
99. Liang Qi, Zhang Ke, Wang S, et al. Acupuncture for cancer pain — an adjuvant therapy for cancer pain relief. *Am J Chin Med*. 2020; 48(8): 1769–1786, doi: [10.1142/S0192415X20500883](#), indexed in Pubmed: [33300479](#).
100. Zhang WT, Jin Z, Cui GH, et al. Relations between brain network activation and analgesic effect induced by low vs. high frequency electrical acupoint stimulation in different subjects: a functional magnetic resonance imaging study. *Brain Res*. 2003; 982(2): 168–178, doi: [10.1016/S0006-8993\(03\)02983-4](#), indexed in Pubmed: [12915252](#).
101. Pariente J, White P, Frackowiak RSJ, et al. Expectancy and belief modulate the neuronal substrates of pain treated by acupuncture. *Neuroimage*. 2005; 25(4): 1161–1167, doi: [10.1016/j.neuroimage.2005.01.016](#), indexed in Pubmed: [15850733](#).
102. Oh JE, Kim SN. Anti-inflammatory effects of acupuncture at ST36 point: a literature review in animal studies. *Front Immunol*. 2021; 12: 813748, doi: [10.3389/fimmu.2021.813748](#), indexed in Pubmed: [35095910](#).
103. Zeng D, Yan X, Deng H, et al. Placebo response varies between different types of sham acupuncture: A randomized double-blind trial in neck pain patients. *Eur J Pain*. 2022; 26(5): 1006–1020, doi: [10.1002/ejp.1924](#), indexed in Pubmed: [35129852](#).
104. Kotani N, Hashimoto H, Sato Y, et al. Preoperative intradermal acupuncture reduces postoperative pain, nausea and vomiting, analgesic requirement, and sympathoadrenal responses. *Anesthesiology*. 2001; 95(2): 349–356, doi: [10.1097/0000542-200108000-00015](#), indexed in Pubmed: [11506105](#).
105. Zhou X, Cao SG, Tan XJ, et al. Effects of transcutaneous electrical acupoint stimulation (TEAS) on postoperative recovery in patients with gastric cancer: a randomized controlled trial. *Cancer Manag Res*. 2021; 13: 1449–1458, doi: [10.2147/CMAR.S292325](#), indexed in Pubmed: [33603487](#).

106. Robinson CL, Berger A, Sottosanti E, et al. Acupuncture as part of multimodal analgesia for chronic pain. *Orthop Rev (Pavia)*. 2022; 14(3): 38321, doi: [10.52965/001c.38321](https://doi.org/10.52965/001c.38321), indexed in Pubmed: [36168395](https://pubmed.ncbi.nlm.nih.gov/36168395/).
107. Wong YK, Wu JM, Zhou G, et al. Antidepressant monotherapy and combination therapy with acupuncture in depressed patients: a resting-state functional near-infrared spectroscopy (fnirs) study. *Neurotherapeutics*. 2021; 18(4): 2651–2663, doi: [10.1007/s13311-021-01098-3](https://doi.org/10.1007/s13311-021-01098-3), indexed in Pubmed: [34431029](https://pubmed.ncbi.nlm.nih.gov/34431029/).
108. Pei L, Geng H, Guo J, et al. Effect of acupuncture in patients with irritable bowel syndrome: a randomized controlled trial. *Mayo Clin Proc*. 2020; 95(8): 1671–1683, doi: [10.1016/j.mayocp.2020.01.042](https://doi.org/10.1016/j.mayocp.2020.01.042), indexed in Pubmed: [32499125](https://pubmed.ncbi.nlm.nih.gov/32499125/).
109. Berger AA, Liu Y, Nguyen J, et al. Efficacy of acupuncture in the treatment of fibromyalgia. *Orthop Rev (Pavia)*. 2021; 13(2): 25085, doi: [10.52965/001c.25085](https://doi.org/10.52965/001c.25085), indexed in Pubmed: [34745475](https://pubmed.ncbi.nlm.nih.gov/34745475/).
110. Ben-Arye E, Hausner D, Samuels N, et al. Impact of acupuncture and integrative therapies on chemotherapy-induced peripheral neuropathy: A multicentered, randomized controlled trial. *Cancer*. 2022; 128(20): 3641–3652, doi: [10.1002/cncr.34422](https://doi.org/10.1002/cncr.34422), indexed in Pubmed: [35960141](https://pubmed.ncbi.nlm.nih.gov/35960141/).
111. Ben-Arye E, Gamus D, Samuels N, et al. Acupuncture and integrative oncology for taxane-induced peripheral neuropathy: a randomized multicentered study. *Int J Gynecol Cancer*. 2023; 33(5): 792–801, doi: [10.1136/ijgc-2022-004004](https://doi.org/10.1136/ijgc-2022-004004), indexed in Pubmed: [36600535](https://pubmed.ncbi.nlm.nih.gov/36600535/).
112. Jin M, Xie L, Mao Ni, et al. The characteristics of registered acupuncture clinical trials enrolling cancer patients. *Support Care Cancer*. 2022; 30(12): 10461–10470, doi: [10.1007/s00520-022-07331-9](https://doi.org/10.1007/s00520-022-07331-9), indexed in Pubmed: [36048280](https://pubmed.ncbi.nlm.nih.gov/36048280/).
113. Halámková J, Dymáčková R, Adámková Krákorová D. Acupuncture from the perspective of evidence-based medicine — options of clinical use based on National Comprehensive Cancer Network (NCCN) guidelines. *Klin Onkol*. 2022; 35(2): 94–99, doi: [10.48095/ccko202294](https://doi.org/10.48095/ccko202294), indexed in Pubmed: [35459333](https://pubmed.ncbi.nlm.nih.gov/35459333/).
114. Brøndum L, Markfoged B, Finderup J. Acupuncture as a tool to reduce nausea in terminally ill patients. *Scand J Caring Sci*. 2022; 36(4): 1046–1053, doi: [10.1111/scs.12991](https://doi.org/10.1111/scs.12991), indexed in Pubmed: [33894009](https://pubmed.ncbi.nlm.nih.gov/33894009/).
115. Meng Z, Garcia MK, Hu C, et al. Randomized controlled trial of acupuncture for prevention of radiation-induced xerostomia among patients with nasopharyngeal carcinoma. *Cancer*. 2012; 118(13): 3337–3344, doi: [10.1002/cncr.26550](https://doi.org/10.1002/cncr.26550), indexed in Pubmed: [22072272](https://pubmed.ncbi.nlm.nih.gov/22072272/).
116. Mao J, Ismaila N, Bao T, et al. Integrative medicine for pain management in oncology: society for integrative oncology-ASCO guideline. *J Clin Oncol*. 2022; 40(34): 3998–4024, doi: [10.1200/jco.22.01357](https://doi.org/10.1200/jco.22.01357), indexed in Pubmed: [36122322](https://pubmed.ncbi.nlm.nih.gov/36122322/).
117. Harris RE, Zubieta JK, Scott DJ, et al. Traditional Chinese acupuncture and placebo (sham) acupuncture are differentiated by their effects on mu-opioid receptors (MORs). *Neuroimage*. 2009; 47(3): 1077–1085, doi: [10.1016/j.neuroimage.2009.05.083](https://doi.org/10.1016/j.neuroimage.2009.05.083), indexed in Pubmed: [19501658](https://pubmed.ncbi.nlm.nih.gov/19501658/).
118. Prinsloo S, Rosenthal DI, Garcia MK, et al. Cross-cultural brain activity differences between true and sham acupuncture for xerostomia during head and neck cancer radiotherapy. *Integr Cancer Ther*. 2022; 21, doi: [10.1177/15347354221101630](https://doi.org/10.1177/15347354221101630), indexed in Pubmed: [35603438](https://pubmed.ncbi.nlm.nih.gov/35603438/).
119. Lau CHY, Wu X, Chung VCH, et al. Acupuncture and related therapies for symptom management in palliative cancer care: systematic review and meta-analysis. *Medicine (Baltimore)*. 2016; 95(9): e2901, doi: [10.1097/MD.0000000000002901](https://doi.org/10.1097/MD.0000000000002901), indexed in Pubmed: [26945382](https://pubmed.ncbi.nlm.nih.gov/26945382/).
120. Romeo MJ, Parton B, Russo RA, et al. Acupuncture to treat the symptoms of patients in a palliative care setting. *Explore (NY)*. 2015; 11(5): 357–362, doi: [10.1016/j.explore.2015.06.001](https://doi.org/10.1016/j.explore.2015.06.001), indexed in Pubmed: [26254221](https://pubmed.ncbi.nlm.nih.gov/26254221/).
121. Fink J, Burns J, Perez Moreno AC, et al. A quality brief of an oncological multisite massage and acupuncture therapy program to improve cancer-related outcomes. *J Altern Complement Med*. 2020; 26(9): 820–824, doi: [10.1089/acm.2019.0371](https://doi.org/10.1089/acm.2019.0371), indexed in Pubmed: [32924553](https://pubmed.ncbi.nlm.nih.gov/32924553/).